{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825895650519552.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood-2011-01-329821"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/117/23/6375/1340753/zh802311006375.pdf"}}],"dc:title":[{"@value":"Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n               <jats:p>Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P = .47, and HR = 0.68, P = .18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P = .39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P < .0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825895650519682","@type":"Researcher","foaf:name":[{"@value":"Gérard Socié"}],"jpcoar:affiliationName":[{"@value":"Service d'Hématologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519687","@type":"Researcher","foaf:name":[{"@value":"Claudia Schmoor"}],"jpcoar:affiliationName":[{"@value":"Clinical Trials Center Universitätsklinikum Freiburg, Freiburg, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519684","@type":"Researcher","foaf:name":[{"@value":"Wolfgang A. Bethge"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Universitätsklinikum Tübingen, Tübingen, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519554","@type":"Researcher","foaf:name":[{"@value":"Hellmut D. Ottinger"}],"jpcoar:affiliationName":[{"@value":"Klinik und Poliklinik für KMT, Universitätsklinikum Essen, Essen, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519689","@type":"Researcher","foaf:name":[{"@value":"Matthias Stelljes"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Universitätsklinik Münster, Münster, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519555","@type":"Researcher","foaf:name":[{"@value":"Axel R. Zander"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519552","@type":"Researcher","foaf:name":[{"@value":"Liisa Volin"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519688","@type":"Researcher","foaf:name":[{"@value":"Tapani Ruutu"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519690","@type":"Researcher","foaf:name":[{"@value":"Dominik A. Heim"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology, Universitätsspital Basel, Basel, Switzerland;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519681","@type":"Researcher","foaf:name":[{"@value":"Rainer Schwerdtfeger"}],"jpcoar:affiliationName":[{"@value":"Centre of Blood and Bone Marrow Transplantation, Stiftung Deutsche Klinik für Diagnostik, Wiesbaden, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519553","@type":"Researcher","foaf:name":[{"@value":"Karin Kolbe"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Universitätsmedizin der Johannes-Gutenberg-Universität Mainz, Mainz, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519683","@type":"Researcher","foaf:name":[{"@value":"Jiri Mayer"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Hemato-oncology, University Hospital Brno, Brno, Czech Republic;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519685","@type":"Researcher","foaf:name":[{"@value":"Johan A. Maertens"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology, I.K. UZ Gasthuisberg, Leuven, Belgium;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519559","@type":"Researcher","foaf:name":[{"@value":"Werner Linkesch"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology, Medizinisches Universitätsklinikum Graz, Graz, Austria;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519560","@type":"Researcher","foaf:name":[{"@value":"Ernst Holler"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Klinikum der Universität Regensburg, Regensburg, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519680","@type":"Researcher","foaf:name":[{"@value":"Vladimir Koza"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Charles University Hospital, Plzen, Czech Republic;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519557","@type":"Researcher","foaf:name":[{"@value":"Martin Bornhäuser"}],"jpcoar:affiliationName":[{"@value":"Center for Bone Marrow Transplantation, Universitätsklinikum Carl Gustav Carus, Dresden, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519693","@type":"Researcher","foaf:name":[{"@value":"Hermann Einsele"}],"jpcoar:affiliationName":[{"@value":"Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519556","@type":"Researcher","foaf:name":[{"@value":"Hans-Jochem Kolb"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology, Klinikum Großhadern, München, Germany; and"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519691","@type":"Researcher","foaf:name":[{"@value":"Hartmut Bertz"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg, Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519558","@type":"Researcher","foaf:name":[{"@value":"Matthias Egger"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg, Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519686","@type":"Researcher","foaf:name":[{"@value":"Olga Grishina"}],"jpcoar:affiliationName":[{"@value":"Clinical Trials Center Universitätsklinikum Freiburg, Freiburg, Germany;"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895650519692","@type":"Researcher","foaf:name":[{"@value":"Jürgen Finke"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg, Germany"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00064971"},{"@type":"EISSN","@value":"15280020"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2011-06-09","prism:volume":"117","prism:number":"23","prism:startingPage":"6375","prism:endingPage":"6382"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/117/23/6375/1340753/zh802311006375.pdf"}],"createdAt":"2011-04-05","modifiedAt":"2019-11-17","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050013784278805760","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004233397371008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Risk factors and organ involvement of chronic GVHD in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004233397535488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236772596736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283691763617664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710484740224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Positive impact of chronic graft‐versus‐host disease on the outcome of patients with <i>de novo</i> myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single‐center analysis of 115 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181473754624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prophylactic and therapeutic treatment of graft-versus-host disease in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186713681664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189390694272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Lasting Graft-Derived Donor T Cells Contribute to the Pathogenesis of Chronic Graft-versus-Host Disease in Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118717550976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588381048261760","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593673180288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood-2011-01-329821"},{"@type":"CROSSREF","@value":"10.1038/bmt.2013.151_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1038/bmt.2015.268_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2018025643_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1016/j.jcyt.2022.05.009_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1038/bmt.2017.153_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1111/ejh.12214_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1007/s12185-015-1784-2_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1182/blood-2015-08-662874_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.3389/fimmu.2017.01842_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1016/j.jtct.2021.02.035_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1016/j.jtct.2024.09.026_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"},{"@type":"CROSSREF","@value":"10.1016/j.jtct.2021.12.009_references_DOI_UC1C8y7HmJnwlPLlZ3hKWAb636x"}]}